Cargando…

Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis

Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Na, Zhang, Yan-Qiong, Jiang, Quan, Liu, Wei, Liu, Jian, Huang, Qing-Chun, Wu, Kuan-Yu, Tu, Sheng-Hao, Zhou, Zu-Shan, Chen, Wei-Heng, Li, Xiao-Xia, Ding, Ying, Fang, Yong-Fei, Liu, Jian-Ping, Li, Zhen-Bin, He, Dong-Yi, Chen, Yao-Long, Lou, Yu-Qian, Tao, Qing-Wen, Wang, Qing-Wen, Jin, Ying-Hui, Liao, Xing, Li, Tai-Xian, Wang, Xiao-Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845140/
https://www.ncbi.nlm.nih.gov/pubmed/33519474
http://dx.doi.org/10.3389/fphar.2020.608703
_version_ 1783644496381083648
author Lin, Na
Zhang, Yan-Qiong
Jiang, Quan
Liu, Wei
Liu, Jian
Huang, Qing-Chun
Wu, Kuan-Yu
Tu, Sheng-Hao
Zhou, Zu-Shan
Chen, Wei-Heng
Li, Xiao-Xia
Ding, Ying
Fang, Yong-Fei
Liu, Jian-Ping
Li, Zhen-Bin
He, Dong-Yi
Chen, Yao-Long
Lou, Yu-Qian
Tao, Qing-Wen
Wang, Qing-Wen
Jin, Ying-Hui
Liao, Xing
Li, Tai-Xian
Wang, Xiao-Yue
author_facet Lin, Na
Zhang, Yan-Qiong
Jiang, Quan
Liu, Wei
Liu, Jian
Huang, Qing-Chun
Wu, Kuan-Yu
Tu, Sheng-Hao
Zhou, Zu-Shan
Chen, Wei-Heng
Li, Xiao-Xia
Ding, Ying
Fang, Yong-Fei
Liu, Jian-Ping
Li, Zhen-Bin
He, Dong-Yi
Chen, Yao-Long
Lou, Yu-Qian
Tao, Qing-Wen
Wang, Qing-Wen
Jin, Ying-Hui
Liao, Xing
Li, Tai-Xian
Wang, Xiao-Yue
author_sort Lin, Na
collection PubMed
description Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 2019 edition of Medicine Catalog for National Basic Medical Insurance, Injury Insurance, and Maternity Insurance. However, individual differences in TGT/TWT response across patients usually exist in the process of treating RA, implying that the clinical application of the two agents may not be standardized leading to the ineffective treatment and the risk of side effects. Growing evidence show that the bioactive constituents of TwHF may often have toxicity, the package insert of TGT and TWT may not be described in detail, and the therapeutic windows of the two agents are narrow. Thus, it is an urgent task to develop a standardized clinical practice guideline for TGT and TWT in the treatment of RA. In the current study, a group of clinical experts of traditional Chinese medicine and Western medicine in the research field of rheumatism diseases, pharmacists, and methodologists of evidence-based medicine were invited to select the clinical questions, to determine the levels of the evidence and the strength of the recommendations, and to develop the recommendations and good practice points. The guideline is formed based on the combination of clinical research evidence and expert experience (evidence-based, consensus, supplemented by experience). The clinical problems which are supported by clinical evidence may form recommendations, and the clinical problems without clinical evidence may form experts’ suggestions. Both recommendations and experts' suggestions in this guideline summarized the clinical indications, usage, dosage, combined medication, and safety of TGT and TWT against RA systematically and comprehensively, which may offer a professional guidance in the context of the clinical application of the two TwHF-based agents.
format Online
Article
Text
id pubmed-7845140
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78451402021-01-30 Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis Lin, Na Zhang, Yan-Qiong Jiang, Quan Liu, Wei Liu, Jian Huang, Qing-Chun Wu, Kuan-Yu Tu, Sheng-Hao Zhou, Zu-Shan Chen, Wei-Heng Li, Xiao-Xia Ding, Ying Fang, Yong-Fei Liu, Jian-Ping Li, Zhen-Bin He, Dong-Yi Chen, Yao-Long Lou, Yu-Qian Tao, Qing-Wen Wang, Qing-Wen Jin, Ying-Hui Liao, Xing Li, Tai-Xian Wang, Xiao-Yue Front Pharmacol Pharmacology Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 2019 edition of Medicine Catalog for National Basic Medical Insurance, Injury Insurance, and Maternity Insurance. However, individual differences in TGT/TWT response across patients usually exist in the process of treating RA, implying that the clinical application of the two agents may not be standardized leading to the ineffective treatment and the risk of side effects. Growing evidence show that the bioactive constituents of TwHF may often have toxicity, the package insert of TGT and TWT may not be described in detail, and the therapeutic windows of the two agents are narrow. Thus, it is an urgent task to develop a standardized clinical practice guideline for TGT and TWT in the treatment of RA. In the current study, a group of clinical experts of traditional Chinese medicine and Western medicine in the research field of rheumatism diseases, pharmacists, and methodologists of evidence-based medicine were invited to select the clinical questions, to determine the levels of the evidence and the strength of the recommendations, and to develop the recommendations and good practice points. The guideline is formed based on the combination of clinical research evidence and expert experience (evidence-based, consensus, supplemented by experience). The clinical problems which are supported by clinical evidence may form recommendations, and the clinical problems without clinical evidence may form experts’ suggestions. Both recommendations and experts' suggestions in this guideline summarized the clinical indications, usage, dosage, combined medication, and safety of TGT and TWT against RA systematically and comprehensively, which may offer a professional guidance in the context of the clinical application of the two TwHF-based agents. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7845140/ /pubmed/33519474 http://dx.doi.org/10.3389/fphar.2020.608703 Text en Copyright © 2021 Lin, Zhang, Jiang, Liu, Liu, Huang, Wu, Tu, Zhou, Chen, Li, Ding, Fang, Liu, Li, He, Chen, Lou, Tao, Wang, Jin, Liao, Li and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lin, Na
Zhang, Yan-Qiong
Jiang, Quan
Liu, Wei
Liu, Jian
Huang, Qing-Chun
Wu, Kuan-Yu
Tu, Sheng-Hao
Zhou, Zu-Shan
Chen, Wei-Heng
Li, Xiao-Xia
Ding, Ying
Fang, Yong-Fei
Liu, Jian-Ping
Li, Zhen-Bin
He, Dong-Yi
Chen, Yao-Long
Lou, Yu-Qian
Tao, Qing-Wen
Wang, Qing-Wen
Jin, Ying-Hui
Liao, Xing
Li, Tai-Xian
Wang, Xiao-Yue
Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
title Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
title_full Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
title_fullStr Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
title_full_unstemmed Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
title_short Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
title_sort clinical practice guideline for tripterygium glycosides/tripterygium wilfordii tablets in the treatment of rheumatoid arthritis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845140/
https://www.ncbi.nlm.nih.gov/pubmed/33519474
http://dx.doi.org/10.3389/fphar.2020.608703
work_keys_str_mv AT linna clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT zhangyanqiong clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT jiangquan clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT liuwei clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT liujian clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT huangqingchun clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT wukuanyu clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT tushenghao clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT zhouzushan clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT chenweiheng clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT lixiaoxia clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT dingying clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT fangyongfei clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT liujianping clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT lizhenbin clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT hedongyi clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT chenyaolong clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT louyuqian clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT taoqingwen clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT wangqingwen clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT jinyinghui clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT liaoxing clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT litaixian clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis
AT wangxiaoyue clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis